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Preface 4 
Vaccination against infectious diseases has changed the future of the human 5 
species, saving millions of lives every year, both children and adults, and 6 
providing major benefits to society as a whole. However, national and sub-7 
national coverage of vaccination varies greatly and major unmet needs persist. 8 
Whereas scientific progress opens exciting perspectives in terms of new 9 
vaccines, the road from discovery to sustainable implementation can be  long 10 
and rocky, from financing, development and licensing to programme 11 
implementation and public acceptance. Immunisation is one of the best 12 
investments in health and should remain a priority for research, industry, 13 
public health and society.    14 
---------------------------------------------------------------------------------------------------- 15 
On 14 May 1796, 73 years before Nature’s first issue, and inspired by Lady 16 
Montagu’s “variolation” concept, Edward Jenner inoculated 8-year old James 17 
Phipps with cowpox pus to prove that the less virulent cowpox would protect 18 
against smallpox. This experiment was a game changer in medicine and health. 19 
For the first time it was possible to medically prevent infection in a healthy 20 
person. Whereas vaccines were widely introduced in high income countries 21 
since the late 1950s, it took 180 years since Jenner before the Expanded 22 
Programme on Immunisation was launched in 1974, promoting access to 6 23 
essential vaccines in all countries worldwide.  Today, vaccines against  26 24 
infectious diseases are internationally available according to WHO1, although 25 
more have been licensed worldwide, changing the future of the human 26 
species. Others are in experimental public health use, such as Ebola vaccines, 27 
or pilot implementation such as the RTS,s malaria vaccine, and about 240 28 
vaccine candidates are in development2.  The US Centers for Disease Control 29 
and Prevention declared vaccination the number one success story for public 30 
health in the 20th century3. 31 
However, progress in vaccine coverage remains highly uneven, between and 32 
within countries, threatening hard-won progress and raising uncertainty about 33 
how to make further advances. Vaccine-preventable diseases such as measles 34 
are on the rise, and episodes  of vaccine reluctance and refusal are occuring 35 
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globally, questioning one of the most transformative interventions for survival 36 
and health.   37 
This review focuses on preventive immunisation in humans and its impact 38 
(rather than on vaccines themselves), including in low, middle and high income 39 
countries. We discuss the current status of vaccine coverage, as well as unmet 40 
needs, four hurdles to overcome to ensure sustainable immunisation 41 
programmes starting with discovery of a new vaccine, the growing issue of 42 
vaccine confidence, and conclude with a number of opportunities and needed 43 
actions in order to ensure the full potential of immunisation for human health 44 
and society. Vaccine product development challenges for low and middle 45 
income countries, which were recently discussed in separate articles4,5, and 46 
therapeutic vaccines are not discussed.  47 
Vaccines are biological products that induce protective immunity against 48 
infection and disease; they consist of sub-components, killed, or inactivated 49 
organisms which train the immune system for a future response to a natural 50 
infection. They are probably the only medical intervention recommended for 51 
every single individual on the planet. Unlike therapeutics, vaccines are used in 52 
healthy people, demanding a very high standard of safety, and requiring 53 
continuous  monitoring for potential  side effects.  Besides considerations of 54 
safety, effectiveness, impact, and cost, this raises complex governance, 55 
regulatory, and public trust issues. All countries have a national immunisation 56 
plan, often with  goals inspired by the Global Vaccine Action Plan (GVAP) global 57 
immunization goals for 2011-20206.  58 
How immunisation has critically contributed to health and society 59 
It is hard to imagine a world without vaccines. A decade ago, WHO, UNICEF 60 
and the World Bank estimated that routine childhood immunization 61 
programmes were preventing over 2.5 million deaths annually7. With the 62 
increase in vaccine coverage, the growth of populations, and the introduction 63 
of new life-saving vaccines, immunization is  ever more important for survival. 64 
Apart from preventing deaths, vaccines prevent disease and disability, 65 
including in adults and the elderly. In a high income country such as the USA, 66 
for a single birth cohort, vaccines prevent nearly 20 million cases of disease, 67 
and over 40,000 deaths8.  68 
A vaccine has for the first time in history eradicated a human disease, 69 
smallpox. Efforts to eradicate polio are in the final stages with only two 70 
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countries, Afghanistan and Pakistan still experiencing wild polio virus 71 
transmission. All countries except 13, have eliminated neonatal and maternal 72 
tetanus. Without vaccination, there would be far more infections requiring 73 
antibiotic therapy, exacerbating the major problem of drug resistant infections.  74 
Between 1990 and 2017,  immunisation contributed to a 55% global decline in 75 
under-5 mortality with a drop from 87 to 39 deaths per 1000 live births9. Over 76 
14 million deaths are estimated to be prevented through measles vaccination 77 
alone between 2011 and 20206. 78 
Vaccination benefits not only those who are vaccinated, but others in their 79 
family and community. This population wide benefit, called “herd immunity”, 80 
reduces the exposure of unvaccinated individuals to pathogens through a 81 
reduction or interruption of the chains of transmission.  A recent study in 82 
Kenya not only showed that the introduction of a pneumococcal vaccine 83 
resulted in a major reduction in invasive pneumococcal disease, but also a 84 
nearly 100% decline in incidence among infants too young to be vaccinated, 85 
and over 74% reduction among unvaccinated children10. Community- or herd 86 
immunity is an important consideration when estimating the full public health 87 
value of immunisation. The threshold to achieve such community protection 88 
can be as high as 95% for measles, but as low as 80% for rubella, and 60% in 89 
high income settings for the effect to begin for pneumococcal vaccination, 90 
meaning the programme strength required to derive additional impact varies 91 
substantially by vaccine11-13. These differences of required critical vaccination 92 
coverage rates are due to R014, the basic reproductive ratio of an infection, 93 
which can vary greatly among various infectious diseases. R0 of a specific 94 
infection indicates the average number of cases one case generates in a 95 
population- in the case of measles it is 12 to 18, which is among the highest15. 96 
It is an indicator of how contagious an infection is, and determines the 97 
minimum level of vaccination coverage needed to generate herd immunity. 98 
Potential long-term effects beyond direct protection against a specific 99 
pathogen or disease have been attributed to a number of vaccines, in 100 
particular the BCG vaccine against tuberculosis and measles vaccine, where  101 
observational studies suggested a survival advantage compared to children 102 
who had remained unvaccinated. These non-specific effects (also called 103 
heterologous) would add to the disease-specific, proven benefits of vaccines, 104 
and have been attributed to epigenetic changes in innate immune cells as 105 
opposed to the adaptive immunity induced by the antigen-specific responses 106 
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to the vaccine16,17. However, the importance of heterologous effects remains 107 
controversial and plausible immunological findings still need to be validated in 108 
large-scale clinical trials. 109 
The benefits of vaccines in general go beyond health, and include economic, 110 
educational, health security and other benefits18. Their full economic value is 111 
not sufficiently quantified in assessments of cost-benefit, nor in investment 112 
terms, and is an increasing area of inquiry and empiric measurement19.  113 
Vaccination is a sound investment. Thus, the return on investment from 114 
childhood immunization in Low and Middle Income Countries (LMIC) is high. 115 
For every $1 invested in immunization against 10 diseases, $16 to $18 are 116 
saved in health care costs, and the net return is as high as $44 per dollar spent 117 
when the broad economic benefits are considered, though return on the 118 
investment varies by individual vaccine20. This is compared with the cost per 119 
DTPcv3 (having received all three doses of DTP containing vaccine) vaccinated 120 
child of $2721. In the USA, net economic benefits of vaccination in one birth 121 
cohort amount to almost $69 million22.  122 
Modelling and observational data suggest that in LMIC vaccination contributes 123 
to poverty alleviation and protection. Financial risk protection benefits of 124 
vaccination are accrued by the poorest households through reduction of 125 
catastrophic and impoverishing health expenditures23,24. There is also evidence 126 
that vaccination improves childhood physical development, educational 127 
outcomes, and equity in distribution of health gains25. Finally, without 128 
vaccines, absenteeism from school and work would be much higher, and 129 
periodic epidemics would disrupt society. The economic impact of periodic 130 
influenza epidemics for example is enormous26-28, and can be reduced by 131 
immunization29.   132 
Vaccination is a life time investment (Figure 1) 133 
In addition to being the backbone of maternal and child health, vaccines 134 
provide important health benefits for all stages in life. Given adaptations of the 135 
immune system throughout life, not all vaccines work equally well at all stages 136 
of life or in all geographical regions30,31. 137 
Starting in infancy, the presence of maternal antibodies in the newborn can 138 
impede vaccine response, as the neonatal immune system undergoes its own 139 
journey of ontogeny, which allows its adaptation from the “sterile” in utero 140 
environment to the confrontation with colonising and potentially pathogenic 141 
microorganisms32. Particular immunologic pathways have been identified33.  142 
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Despite significant progress in reducing under-5 mortality, important gaps 143 
remain in addressing neonatal morbidity and mortality. Neonates are 144 
particularly vulnerable to infection with gram-negative bacteria and Group B 145 
streptococcus, for which no neonatal vaccines currently exist33,34. The gap in 146 
early protection can potentially be bridged by administering vaccines to 147 
women in pregnancy, relying on passively transferred antibody to protect 148 
infants in the first few months of life, until vaccinations administered in infancy 149 
or later can provide protection.  Based on this principle, tetanus, influenza and 150 
pertussis vaccination are recommended for pregnant women to prevent 151 
neonatal infections, such as neonatal tetanus35. This maternal immunisation 152 
strategy may be expanded with promising vaccines against Group B 153 
streptococcus and Respiratory Syncytial Virus36. 154 
For adolescents, lifesaving vaccines against human papilloma virus (the cause 155 
of cervical, anal, penile and head and neck cancers) are being increasingly  156 
introduced and must be administered prior to the likely acquisition of HPV via 157 
sexual contacts.  Vaccines against meningococcal meningitis, a potentially 158 
lethal infection with a second peak in adolescence, have also been introduced 159 
into this age group in some countries. New platforms such as schools had to be 160 
engaged to administer these vaccines . 161 
 Outbreaks of mumps have very occasionally been seen in teenagers, despite a 162 
solid vaccination record. This highlights the need for surveillance of all age 163 
groups for outbreaks and could be due to waning of protection induced by 164 
vaccines otherwise regarded as highly efficacious37-39.  165 
Booster vaccines against diphtheria, tetanus and polio are required to 166 
guarantee long-lasting protection and are required throughout adulthood to 167 
maintain protective immunity levels – though recommendations may vary by 168 
country.  169 
 170 
A life course approach to vaccination has become ever more pressing with 171 
pneumonia, influenza and shingles differentially affecting older adults, and 172 
death rates from pneumonia and influenza are 130  times higher for adults 173 
over 85, as compared to younger adults40.  Vaccination of the elderly with 174 
existing vaccines could prevent up to 90 000 deaths per year in the United 175 
States alone41.   176 
Adult immunization does not have a clear prioritization in low- and middle 177 
income countries, and is a complex programme across high income countries. 178 
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It is different from pediatric immunization  which has a global programme and 179 
focused, substantial funding. As the demographics are shifting across the world 180 
to an older distribution a focus on adult immunization will become increasingly 181 
relevant, as advocated by the World Coalition on Adult Immunization42. 182 
Despite national recommendations43,44, vaccine coverage among adults in high 183 
income countries is uneven45 (vaccine coverage for herpes zoster among adults 184 
aged ≥60 was 24% compared with 65% for influenza among those aged ≥65 in 185 
the US), and very low or not even available in most low and middle income 186 
countries46. Yet, several studies have shown good cost-effectiveness of adult 187 
vaccinations against influenza, pneumococcal infection, shingles, human 188 
papilloma virus and tetanus-diphtheria-pertussis47.  189 
 Important gaps also exist in our understanding of fundamental biology of adult 190 
immunisation.  Due to “immunosenescence,” vaccination of older adults is in 191 
general not as effective as in younger people, but the reasons for poorer 192 
responsiveness are not well defined, requiring a new effort in terms of 193 
strategies and products for immunization of adults. However, it is likely that 194 
several compartments of the immune system are affected48. 195 
There are three areas where alterations to increase vaccine efficacy in the 196 
elderly could be considered: (i) increase vaccine potency; (ii) use adjuvants to 197 
enhance immunity; and (iii) apply immune modulators or other interventions 198 
to alter host immunity generally.  199 
As populations age across the world, it will be increasingly important to 200 
identify how to integrate immunisation programmes in health and care 201 
services to reach all age groups.   202 
In addition, travel, certain professions or health conditions require specific 203 
vaccinations49-51, and international travel has played a role in the resurgence of 204 
measles in the USA and elsewhere52. 205 
From discovery to impact : overcoming four major hurdles  206 
There are still major infectious diseases whose control and ultimate 207 
elimination would require an effective vaccine, such as HIV infection and 208 
tuberculosis. Therefore continuing development of new vaccines is a public 209 
health imperative. Unfortunately, the majority of early vaccine candidates in 210 
discovery phase never make it as a safe and effective product. Development 211 
and deployment of vaccines is a long and complex process. We describe here 212 
 7
briefly four hurdles that have to be overcome from the discovery phase of a 213 
new vaccine to sustainable population impact.(Table 2).   214 
The first hurdle is a so-called “valley of death” from discovery to early clinical 215 
development, when a potential antigen, adjuvant or new vaccine formulation  216 
developed in the laboratory is  further tested for clinical proof of concept and 217 
safety in humans, in addition to optimizing production elements. Real progress 218 
has been made in recent years thanks to a number of public and private 219 
initiatives, which are helping partly to overcome this first major challenge , 220 
such as CEPI, the Coalition for Epidemic Preparedness Innovation53 created 221 
after the 2014-2015 Ebola epidemic in West Africa to accelerate development 222 
of vaccines against epidemic pathogens2,4,54. 223 
The second hurdle in vaccine development, also referred to as “second valley 224 
of death”, relates to the shift from early clinical development to the large and 225 
very expensive efficacy trials most often needed4, unless a previous similar 226 
vaccine is already developed and a new product can be licensed using an 227 
established  correlate of protection. This is also the most expensive phase of 228 
vaccine development, absorbing over two thirds of the total costs of 229 
development of a new vaccine, including building special manufacturing 230 
facilities and conducting Phase 3 trials in several countries, ideally with 231 
independent research partners. Often, this major financial effort is beyond the 232 
means of smaller biotech companies, and in general only big pharmaceutical 233 
companies and large foundations or public institutions have the financial 234 
bandwidth to support such trials which can cost as much as hundreds of 235 
millions of dollars. For vaccine candidates without a prospect of a high income 236 
market, ensuring return on investment, when the potential market for the new 237 
vaccine is limited to low and middle income countries, there is a quasi 238 
unsurmountable valley of death unless philanthropic and public funding 239 
intervene2.  240 
 The needs and unique challenges of vaccines against epidemic pathogens 241 
demand innovation in product development pathways. The Merck  rVSV  Ebola 242 
vaccine has been deployed on a large scale during the outbreak in eastern DR 243 
Congo prior to product licensure, even for indications for which no efficacy 244 
data are available such as primary prevention in health care workers. Well 245 
informed country leadership and transparent governance of such use are 246 
critical, as is genuine community involvement.  The “animal efficacy rule” when 247 
human efficacy trials are not feasible or ethical55, should also be considered for 248 
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vaccines against epidemic pathogens. The development of Ebola vaccines has 249 
shown how this type of ‘learning by doing’ model, can offer early access in 250 
humanitarian situations 56,57, though it should be stressed that nearly five years 251 
after the first Ebola vaccine clinical trials in West Africa, no Ebola vaccine is 252 
licensed despite well documented immunogenicity, safety, and human and/or 253 
non-human primate efficacy data. When a crisis such as Ebola is no longer 254 
head line news, the sense of urgency is lost, and regulators and normative 255 
committees go back to often extraordinarily long processes.  256 
Following a successful phase 3 trial, there is a complex road to  licensure of any  257 
new vaccine, requiring reproducibility and safety tests of multiple batches of 258 
vaccines,  while manufacturing facilities are finalized. Several countries still 259 
request clinical trial data conducted locally, delaying country licensure and 260 
implementation  significantly, while further raising costs of development. In 261 
Europe there is advanced harmonization in regulatory approval of vaccines 262 
through the European Medicines Agency, and in sub-Saharan Africa the Africa 263 
Vaccine Regulatory Forum (AVAREF) is aiming to strengthen regulatory 264 
capacity for clinincal trials and harmonization of regulatory practices58.    265 
Following all of these activities which can take as long as ten years or more, a 266 
new vaccine is now ready for deployment, but  a third hurdle can occur 267 
between licensure of a vaccine and broad scale implementation, which is 268 
dependent on both a policy recommendation and the ability to implement. 269 
Many years can go by before important new vaccines reach communities in 270 
need, the cost of which is measured in human lives that could have been saved 271 
as well as  money for their development.  272 
There are many contributors to this third hurdle: first is cost, especially 273 
relevant for countries that are neither wealthy enough to procure vaccines at 274 
high cost, nor poor enough to receive funding assistance from Gavi  the 275 
Vaccine Alliance. However, when a Gavi eligible country transitions out of the 276 
program on the basis of an increase of it’s GNI per capita, it must increasingly 277 
mobilise domestic resources or other development assitance59.    Even when 278 
the broader value proposition of a new vaccine is substantial, there remains 279 
the question of affordability. Second, is the question of country capacity to 280 
take on new vaccines: the past decade has been an extraordinary era for 281 
vaccine introduction with 113 countries having introduced at least one new 282 
vaccine – a real success story60. Country capacity to introduce and sustain ever 283 
growing programmes involves human and financial resources, and time to 284 
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build political support and community demand. Both pneumococcal conjugate 285 
vaccine and rotavirus vaccine now have coverage in low income Gavi countries 286 
that meets or exceeds the global average, however this reflects that not all 287 
countries in any income strata have yet introduced these vaccines in spite of 288 
their availability61. Even high income countries can experience delays. Thus, in 289 
the UK, a meningococcal B vaccine was licensed in January 2013, 290 
recommended for introduction in March 2014 and finally announced for 291 
introduction in May 2015. It then took over 12 months to resolve procurement 292 
discussions to enable implementation62. 293 
For products that address priority diseases for low income countries the 294 
uncertainty of the market may risk products collapsing unless a full end-to-end 295 
product solution is articulated, with non-commercial support . Inclusion of the 296 
new vaccine in WHO’s Pre-qualification list is a requirement for procurement 297 
through Unicef and  Gavi and other funders. Some of these are vaccines 298 
against parasitic diseases, which are much more complex than bacterial or viral 299 
vaccines due to the the wide range of antigens with often a complex life cycle 300 
exhibiting different antigens relevant for vaccine protection. Thus the RTS,s 301 
vaccine, the first ever malaria vaccine deployed in a routine immunization 302 
system63, took nearly 30 years since it’s creation by GSK in 198764  before EMA 303 
issued a positive scientific opinion in 2015, and in 2016 WHO recommended 304 
large scale pilot programmes. These took another three years to start in 305 
several African countries, and illustrate the sometimes extraordinary long 306 
development, licensure, and introduction times. It is also an example of a 307 
vaccine whose clinical trial performance of partial protection  led to a policy 308 
decision to advance in a step-wise manner rather than full programmatic 309 
deployment. This may become a more common pathway for future products, 310 
in part because these vaccines have performance and implementation 311 
characteristics that are more complex than those of current vaccines.   312 
We are entering an era where the path from vaccine licensure to routine 313 
implementation requires more than safety and efficacy data. Policy 314 
recommendations for new vaccines may only be realized following 315 
implementation research to determine how to most effectively ensure use and 316 
impact.  Cost effectiveness deliberations, full value of vaccine assessments, and 317 
country priorities in the face of constrained resources remain drivers for delays 318 
associated with the third hurdle . National immunisation technical advisory 319 
groups (NITAGS) will be increasingly important to guide evidence based 320 
decision making.  321 
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Even after the lengthy and costly trajectory to introduce a new vaccine, 322 
ensuring sustainable impact faces a fourth set of hurdles that must be 323 
overcome. These include supply and demand sustainability, and resilience and 324 
acceptance of immunisation. Logistical issues such as in-country cold chain, 325 
procurement management, and the organisation of vaccination clinics in 326 
remote areas, vaccine hesitancy, equity of access can all present challenges. In 327 
addition, the misuse of vaccination campaigns as political tools has seriously 328 
damaged vaccine confidence in areas such as the Philippines, Nigeria, 329 
Afghanistan, Italy and Pakistan65. Some side effects or limitations of duration of 330 
protection may only become obvious after larger scale use, such as for live oral 331 
rotavirus vaccination in high-mortality settings66, pertussis vaccine67 and 332 
others68. A recent example is the finding from a retrospective analysis of long 333 
term efficacy trials  showing that although there is a clear overall population 334 
benfit of the Dengvaxia vaccine against dengue, the vaccine also  caused an 335 
excessive risk of severe dengue in seronegative vaccinees ( i.e. those not 336 
exposed to dengue virus69).   In the Philippines this new risk was reported after 337 
over 800,000 school children were vaccinated, prompting a dramatic reaction 338 
by the public in 201870.  339 
Stock outs and vaccine manufacturing capacity have been problematic for 340 
certain vaccines, even in high income countries. Manufacturers emphasize the 341 
time needed to build and commission a factory71. Whereas middle income 342 
country manufacturers are now supplying most low cost vaccines globally, they 343 
face low profit margins, ferocious tenders, and often unpredictable 344 
procurement schemes. More efficient and modular production technologies 345 
may allow decentralised production with lower capital costs.  346 
Each of the four hurdles can be overcome, though the fourth one should be a 347 
continuing concern for every national immunisation programme. Depending 348 
on the phase, they may require different sets of actors, and sometimes are a 349 
matter of policy, management and leadership, rather than money.    350 
Throughout development and use of vaccines, vaccine safety is an overriding 351 
concern, and requires a continuous and careful scientific and societal 352 
assessment. Safety monitoring during manufacturing typically occupies a major 353 
part of the process and costs of a vaccine, and is a key element of any vaccine 354 
programme. In specific high income populations, such as in the elderly, 355 
personalized medicine approaches have been proposed  to maximize both 356 
immunogenicitiy and safety in the presence of chronic conditions and changes 357 
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related to older age, but large scale  applicability is questionable for the time 358 
being72-74. 359 
   Persistent unmet needs for vaccination  360 
The extraordinary achievement of vaccines is reflected in countries having 361 
vaccinated over 116 million infants in 2018 alone75, a similar success story to 362 
that of 2017 when a similar number of infants were estimated to have been 363 
vaccinated ---the greatest number, ever. Figure 2 shows global and regional; 364 
coverage of DPT3 vaccination between 1980 and 2018, showing overall high 365 
coverage, with regional variatons, but also stagnation in coverage over the last 366 
10 years76. Nonetheless, there still remained 19.4 million un- or under-367 
vaccinated children, leaving them vulnerable to diseases they could and should 368 
be protected from. In some countries substantial improvements in coverage 369 
have been achieved, while in others coverage is backsliding, often because of 370 
social disruption, conflict, or political upheaval, pointing out the highly dynamic 371 
nature of vaccine programme performance.   372 
Around 60% of all children who did not receive basic immunisation in 2018 live 373 
in 10 countries: , Angola, Brazil, the Democratic Republic of the Congo, 374 
Ethiopia, India, Indonesia, , Nigeria, Pakistan, The Philippines, and Vietnam 77. 375 
To achieve rapid change in this situation requires the full commitment of 376 
governments, supported by international organisations. Gavi provides funding 377 
for vaccination programmes in low- and low-middle income countries and has 378 
had substantial impact. The technical support provided by the Gavi Alliance 379 
partners will be key to addressing persistent gaps.  Consistently delivering 380 
vaccines with high coverage, reaching at least the minimum coverage required 381 
to achieve herd immunity in line with the basic reproductive ratio of an 382 
infection as mentioned above, remains a struggle  in many other countries 383 
including in middle- and high- income settings, with  poor children not being 384 
reached78,79. For example, in the USA in 2017 100,000 children under 2 years 385 
(1.3% of the population of that age) were not immunised against DTP/MMR, a 386 
fourfold increase since 200179,80.  387 
 Of particular concern are countries whose vaccination coverage has declined.  388 
There are 19 countries who had over 80% first dose measles coverage at some 389 
point between 2011-2017 and whose 2018 coverage is at least 10% lower than 390 
their peak coverage.  The measles vaccine coverage of those 19 backsliding 391 
countries now ranges from 38% - 88%, with 10 well below 80%61.  Some of the 392 
backsliding on coverage may represent improvements in data rather than 393 
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actual slippage in coverage.  The data systems to accurately monitor both the 394 
number of children born and the number of children vaccinated  are highly 395 
variable in quality81,82. In some settings management and reward systems likely 396 
incentivize inaccurate reporting of coverage data to meet targets, rather than 397 
incentivizing accurate reporting.  398 
Measles, diphtheria, and yellow fever outbreaks are the result of what 399 
happens when the world is complacent and immunisation coverage declines. 400 
Diphtheria outbreaks surged in Russia in the early 1990s, and among Rohingya 401 
refugees from Myanmar in 2017, outbreaks of meningitis occurred in refugee 402 
camps, and transmission of polio persists in parts of Afghanistan and 403 
Pakistan83. Measles outbreaks are occurring in all regions of the world. The 404 
recent 80-fold increase in reported measles cases in the WHO Europe Region 405 
over 4 years to over 82,000 cases in 2018 with 72 deaths84,85 are a result of a 406 
mix of vaccine refusals, cultural beliefs, and access issues including  407 
interruptions in vaccine supply, such as in Ukraine86, leading to a WHO 408 
declaration of a grade 2 health emergency87. In the Americas, thousands of 409 
cases have been reported in Venezuela due to the political and economic crisis, 410 
with cases also appearing in Brazil, Colombia and Ecuador, resulting in the loss 411 
of regional elimination status granted in 2016.  412 
These outbreaks reflect failures to achieve and maintain high vaccination 413 
coverage, community by community. Low vaccination coverage and high 414 
heterogeneity in coverage are most deeply seen among African countries 415 
where routine immunisation rates in many countries are well below the GVAP 416 
targets88.    417 
Since 2010, routine immunization levels have either stagnated or decreased in 418 
54 of 85 middle income countries, who do not qualify for Gavi support78. 419 
Vaccine expenditures per child are often lower in middle income countries 420 
than in low income Gavi countries.  The issue may not be so much lack of 421 
funding capability, but lack of prioritization of immunization, not participating 422 
in pooled procurement mechanisms such as via Unicef, low volumes, 423 
insufficient efforts to reach vulnerable populations, vaccine choices, and 424 
duplicative local regulatory requirements delaying introduction of new 425 
vaccines.  426 
Another unmet need concerns new vaccine introduction. Rapid progress has 427 
been made to scale up the introduction of vaccines through Gavi investments 428 
in low income countries, but not all vaccines have progressed at the same 429 
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rapid pace. The adolescent HPV vaccine has been particularly slow to be 430 
introduced outside of high income settings because of programmatic 431 
challenges, public access issues, supply constraints and pricing.    432 
Addressing these unmet needs will require both dogged implementation of 433 
strategies that have been shown to be effective, like detailed microplanning of 434 
local efforts to assure all children are identified and immunized, special 435 
campaigns, to implementation of novel approaches like drone delivery of 436 
vaccines in hard to reach areas89. Systematic evaluation and implementation  437 
research should be part of these efforts in order to develop a firm evidence 438 
base for overcoming such programmatic challenges.  The World Health 439 
Organization has elaborated guidance on implementing high impact 440 
immunization programmes (Global Routine Immunization Strategies and 441 
Practices, GRISP) to address these unmet needs. Middle income countries  not  442 
benefiting from  Gavi funding need procurement mechanisms that can secure 443 
more predictable tiered pricing.  No set of strategies, however, will succeed 444 
without substantially enhanced domestic investment and local political 445 
commitment, which continue to limit progress in many parts of the world.  As 446 
demand for services from communities increases, responsiveness to that 447 
demand from governments, the funder of such services in most countries is 448 
more likely90.    449 
In addition to the unmet needs related to existing vaccines, nearly half of all 450 
deaths from infectious diseases are from infections for which no vaccine is  451 
available (e.g. more than 0.5 million deaths under 5 years from enteric 452 
infections for which there is no vaccine91). These should be priorities for 453 
vaccine R&D, while improvements are needed for vaccines such as against 454 
rotavirus, pertussis, polio, and yellow fever. Innovations in delivery devices are 455 
also important (e.g. micro patches, temperature stable vaccines, improved cold 456 
chain equipment). 457 
The Equity Imperative  458 
Equity has been a primary goal of immunization programmes. Reaching those 459 
in greatest need means addressing issues of vaccine availability, affordability, 460 
accessibility, acceptability, and financing.  An effective immunization system 461 
that delivers vaccine with high equity across social and ethnic strata, maternal 462 
and community education, and geographies, is a purpose built programme to 463 
deliver impact, and has been shown to be the critical programmatic target.    464 
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Country level coverage values mask subnational inequity, risking disease 465 
outbreaks and backsliding on achievements of vaccination. Immunization 466 
improvement should focus at the subnational level, as well as on other 467 
determinants of inequity, not all of which would be addressed through focused 468 
supplemental vaccine campaigns.  469 
There is a special case for vaccine development for pathogens that cause 470 
epidemics. These diseases have little to no market incentive to drive product 471 
development hence the need for innovative arrangements  such as CEPI 53, US 472 
BARDA (Biomedical Advanced Research and Development Authority)92 and the 473 
European IMI (Innovative Medicines Initiative) 93,94.  474 
Humanitarian crises are another increasing impediment to immunisation.  The 475 
number, size and duration of conflicts, migration of refugees, and natural 476 
disasters, have caused major disruptions to immunisation programmes and 477 
resulted in serious disease outbreaks. The persisting hurdles to polio 478 
eradication reveal how political, social and conflict situations can disrupt 479 
access to populations and risk violence targeting vaccinators such as in 480 
Pakistan and Afghanistan95. Nearly 100 polio vaccinators and their security 481 
guards have been targeted and killed while attempting to reach children for 482 
vaccination96.  483 
The growing challenge of vaccine confidence  484 
Despite the success and wide-acceptance of the importance of immunization, 485 
there are growing groups of people delaying or refusing vaccines.  In 2013 486 
WHO/SAGE established a working group to investigate the scope and scale of 487 
vaccine hesitancy97, the US National Vaccine Advisory Committee (NVAC) 488 
convened a Vaccine Confidence Working Group to investigate the situation in 489 
the US (National Vaccine Advisory Committee, 2015), and the European Centre 490 
for Disease Prevention and Control (ECDC) published a review of the state of 491 
vaccine hesitancy in Europe98. In January 2019, the World Health Organization 492 
named vaccine hesitancy as one of the top ten global health threats. 493 
Since 2015, the Vaccine Confidence Index™ has surveyed over 300,000 494 
respondents globally to pick up early signals of waning public confidence in 495 
vaccine importance, safety, and effectiveness in order to prompt early 496 
intervention where needed (See Figure 3 for world map of confidence in 497 
vaccine safety in 2018).   The European Commission adopted the Index as part 498 
of a new effort to strengthen cooperation against vaccine-preventable 499 
diseases99, and the Wellcome Global Monitor on Trust in Science and Health as 500 
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part of their 144 country study100. Safety was not only identified as a key issue 501 
in the 2018 European study, but also in a larger 144-country global study using 502 
the VCI™. In the Wellcome Global Monitor, public confidence in vaccine safety 503 
was consistently lower than confidence in vaccine effectiveness and 504 
importance100.  505 
Whereas lack of familiarity by both physicians and parents with many 506 
childhood diseases because of years of successful vaccination programmes 507 
may play a role in a lack of interest in vaccines, the reasons for a decline in 508 
vaccine confidence are far more complex. Newer challenges to vaccine 509 
confidence include social media campaigns which have disrupted measles-510 
rubella vaccination efforts in southern India, collapsed HPV vaccination efforts 511 
in Japan, provoked false scares of vaccine poisoning in Pakistan, and 512 
undermined vaccination programmes in Indonesia.  513 
Vaccine confidence issues are highly varied by setting and vaccine. In a three-514 
year review (2015-2017) of the WHO/UNICEF Joint Reporting Form (JRF) 515 
completed annually by national immunization programmes, over 90% of the 516 
194 countries reported that they experienced vaccine hesitancy. The top three 517 
reasons for hesitancy were “risk-benefit (scientific evidence)” i.e. safety 518 
concerns, “lack of knowledge on benefits of immunization,” and “religion, 519 
culture and socio-economic issues”101.   520 
Challenges around building confidence in vaccine safety are well beyond 521 
communication, although more accessible public communication around the 522 
complex issues of safety and risk benefit analysis are important. What needs to 523 
be addressed is not only better communication around the known, albeit 524 
sometimes misinterpreted, risks and benefits of vaccination, but investing in 525 
more research in the areas where the public is asking questions and the 526 
science is incomplete. Findings that Pandemrix, an AS03-adjuvanted influenza 527 
vaccine, was linked to increased cases of narcolepsy in Europe prompted 528 
further research, but a systematic review concluded that more research is 529 
needed102.  530 
While uncertainty is the norm in science, the political and social worlds of the 531 
public have become less tolerant of ambiguity and risk103. New modes of 532 
listening to the public, with rapidly evolving technologies to monitor social 533 
media, can harvest emerging safety questions as well as pick up signals of 534 
possible issues that need investigation. Working towards better aligned public 535 
questions and accessible, evidence-based answers, should be a goal. The 536 
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Vaccine Safety Net initiative at WHO is an important resource and can be 537 
further built on to address new questions as they emerge, as well as make new 538 
research accessible104. 539 
 Social and political contexts and the reliability of health services are important 540 
levers of trust, and a low trust setting will have less tolerance for risk than one 541 
with high trust. A 2015 study showed that  high trust in immunization services 542 
clearly correlated with lower rates of vaccine hesitancy105.  The public’s 543 
experience with health services and health workers  is highly influential in 544 
vaccine decision, but both are needed. The Wellcome Monitor showed that, in 545 
Japan for example,  despite low trust in vaccines and low trust in government, 546 
confidence in health providers remained high. 547 
Introducing new vaccines into populations requires adequate time to train and 548 
prepare front line health workers and vaccinators to be ready to manage public 549 
questions, and ongoing dialogue between scientists and the public will be 550 
important to build confidence from the start, as well as  anticipate and manage 551 
adverse events. 552 
In the Philippines reported risks of a recently introduced dengue vaccine106 553 
amplified into public outrage mediated through Facebook pages, made more 554 
complex because the events occurred during political elections.  The result was 555 
a dramatic drop in public confidence in vaccines more generally from 99.5% in 556 
2015 to 76.2% in 2018, while confidence in vaccine safety plummeted from 557 
99.5% to 65.2%65. (Figure 4) The overall drop in public trust affected 558 
willingness to accept even the measles vaccine, prompting measles outbreaks 559 
with over 25,000 measles cases and 355 deaths by March 2019107 requiring 560 
considerable efforts to rebuild public confidence and increase vaccine uptake.  561 
 562 
Conflict situations also affect confidence in vaccines and vaccinators due to an 563 
environment of distrust and uncertainty, such as in Pakistan and Afghanistan, 564 
and in the Democratic Republic of Congo where local violence and conflict in 565 
the Ebola affected areas has been an obstacle to vaccination efforts.   566 
The future of immunisation: sustainability and new opportunities 567 
The contribution of immunisation to human health, security and prosperity, 568 
has been matched by few other activities in health and development, and has 569 
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been crucial for progress in child survival. As immunisation coverage among 570 
adults is generally low, it is another area where greater advances can be made. 571 
Addressing the following issues will be crucial to ensure optimizing the impact 572 
of vaccination:  573 
1. Leadership and funding: Achieving immunisation for all those in need 574 
should be a top priority for every country. This will require stronger political 575 
leadership and a continuing increase in investments in immunisation, both 576 
domestically and internationally6. The power of immunisation to achieve wider 577 
health and societal benefits should be further documented.  Prioritization of 578 
vaccines is particularly critical for middle income countries no longer benefiting 579 
from Gavi support and for countries that are transitioning out of Gavi support.  580 
A successful replenishment of Gavi resources in 2020 for the proposed Gavi 5.0 581 
strategy108 is vital for the next decade of progress in child survival, and will be a 582 
test of the international community’s commitment to immunisation and global 583 
health.  584 
2. Universal vaccine coverage and equity: Overcoming the stagnation in 585 
reaching all people in need with even the basic vaccines is an overriding 586 
priority in all countries, especially in those with the lowest coverage and the 587 
greatest number of unvaccinated children. As we look toward the next decade  588 
ensuring that vulnerable people all countries are not left behind should be a 589 
top concern, particularly in middle income countries since there will be more 590 
poor people living there than in poorer countries78. 591 
Ensuring a sustainable and affordable supply of quality vaccines, with 592 
differential pricing according to the wealth of a country, is fundamental to 593 
achieving sustainability and equity of immunisation. Only a few multinational 594 
companies are producing vaccines, and a growing number of middle income 595 
manufacturers are major suppliers. There is a risk that continuous lowering of 596 
prices may lead to new monopolies, and possibly higher prices. Healthy vaccine 597 
markets with sustainable supply is an important objective for vaccine 598 
programmes. Harmonisation and strengthening of regulatory capabilities of 599 
LMIC are key. Initiatives such as the Africa Vaccine Regulatory Forum 600 
(AVAREF)58 deserve support. The fact that some countries require local clinical 601 
trials despite WHO prequalification, can be a source of major delays in the 602 
introduction of vaccines. 603 
3. People-centred   programmes Immunisation programmes can become more 604 
effective with a systems-driven and “precision public health” approach, taking 605 
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into account local variation in immunisation levels, specific needs, cultural 606 
specifics, and circumstances of vulnerable populations. Quality data at 607 
administrative levels closer to communities should be collected to inform 608 
“micro-planning” and  adaptive programme delivery. Thoughtful integration of 609 
immunisation into health services, education systems, and elderly care, among 610 
other innovative efforts are needed.  611 
As most vaccines have incomplete efficacy, tailored approaches to optimize 612 
their impact will be needed particularly for vaccines against malaria, influenza, 613 
dengue, and probably HIV when it becomes available. 614 
4. Vaccine confidence: Vaccine confidence must be addressed up front and be 615 
an integral part of immunisation programmes. Many approaches to increasing 616 
vaccine uptake do not take into account the social, historical and political 617 
realities of the public for whom information alone is not the antidote to 618 
vaccine reluctance. Instead of older demand-creation models, a new model 619 
and language of engaging  with the public is needed, starting with better 620 
listening and prompt responding to concerns as well as building on local 621 
capacities. Inclusion of non-traditional partners, new modes of digital 622 
communication, social scientists, and religious and traditional leaders have 623 
been invaluable in addressing hesitancy around polio vaccination, and the 624 
engagement of teenage girls in co-designing social media outreach to address 625 
HPV vaccination concerns had positive impacts on vaccine uptake in Denmark. 626 
With safety anxieties being reported as one of the top reasons for vaccine 627 
hesitancy, aligning vaccine safety research with dominant safety concerns will 628 
also be important for confidence building.  629 
5. Invest in research and innovation:  Many issues mentioned in the other 630 
recommendations require further research in a wide range of disciplines. 631 
Product innovation as a result of the formidable progress in immunology and 632 
infection pathogenesis has been a strong driver of immunization programmes.  633 
There is reluctance of industry to develop vaccines, when market incentives 634 
are limited, and licensure is uncertain. While companies such as Merck and 635 
Johnson & Johnson invested considerably in the development of Ebola vaccine 636 
candidates, partly supported by public funds in North America and Europe, but 637 
without a prospect of a return on investment, it would be unrealistic to expect 638 
that  industry will follow this example for each new emerging pathogen. There 639 
is a major role for the public sector and philanthropy to support mechanisms 640 
such as CEPI to develop vaccines for low income countries2.  As discussed 641 
under the “2nd hurdle” on the challenge to fund and conduct late clinical 642 
 19
development to market introduction for vaccines for which there is no market 643 
incentive, there is an urgent need to address this gap through possibly a 644 
specific global initiative or at least a concerted action of several funders.   645 
There is also a need for innovation in trial design (for faster trials with smaller 646 
sample size and including collection of valuable biosamples to inform 647 
correlates of protection) and in trial analysis, as well as in vaccine delivery. 648 
Escalating antimicrobial resistance (AMR) is a powerful incentive to develop 649 
vaccines against bacterial infections, malaria, TB and HIV infection109-111. 650 
Innovation in delivery of vaccination programmes is as important as product 651 
innovation.  652 
The world cannot afford to turn the clock back on immunisation, and ever 653 
more innovative vaccines will offer additional opportunities to reduce 654 
mortality and improve quality of life for every person on the planet. This will 655 
require the best of science, entrepreneurship, programme implementation on 656 
the ground, and politics. 657 
  658 
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Table 1. Historic timeline of introduction of vaccines (year of licensure indicated 1030 
wherever possible)1031 
Notes: Adapted from Plotkin & Plotkin (2018)112. a. Capsular polysaccharide conjugated to carrier 1032 
proteins. b. An investigational vaccine, rVSV-ZEBOV, was used under “expanded access” during the 1033 
Ebola outbreak in west Africa in 2015 and the 2018 outbreak in DR Congo. c. Positive opinion from 1034 
EMA under article 58 issued in 2015.  Approved for routine use in pilot implementation settings in 1035 
Ghana, Malawi, Kenya in 2018.  d. Reverse vaccinology. WC: whole cell. rBS: recombinant B subunit.  1036 
 29
Year Disease  Year Disease  
1798 Smallpox 1999 Rotavirus (reassortant)  
1885 Rabies 2000 Pneumococcal conjugate (heptavalent) a 
1896 Cholera 2003 Influenza (intranal, cold-adapted) 
1896 Typhoid 2005 Meningococcal conjugates (quadrivalent) a 
1897 Plague 2006 Human papillomavirus recombinant (4-valent)  
1923 Diphtheria toxoid  2006 Rotavirus (attenuated and new reassortants)  
1926 Pertussis (WC) 2006 Varicella Zoster 
1926 Tetanus toxoid  2008 Rotavirus (monovalent)  
1927 Tuberculosis (bacille Calmette-Guérin)  2009 Japanese encephalitis  (Vero cell) 
1935 Yellow fever  2009 Cholera (WC only)  
1936 Influenza  2009 Human papillomavirus recombinant (2-valent)  
1937 Tickborne encephalitis  2010 Meningococcal type A conjugate (monovalent) 
1938 Typhus  2010 Pneumococcal conjugate (13-valent)  
1955 Polio (inactivated)  2014 Human papillomavirus (9-valent)  
1963 Measles  2014 Meningococcal type B (fH factor)  
1963 Polio (oral) 2015 Ebola (unlicensed) b 
1967 Mumps  2015 Malaria c 
1969 Rubella  2015 Dengue  
1970 Anthrax secreted proteins  2015 Meningococcal type B d 
1974 Meningococcus polysaccharide  2016 Cholera (oral)  
1977 Pneumococcus polysaccharide (14-valent)  2018 Typhoid conjugatea 
1980 Adenovirus  2006 Human papillomavirus recombinant (4-valent)  
1980 Rabies (cell culture)  2006 Rotavirus (attenuated and new reassortants)  
1981 Tickborne encephalitis  2006 Varicella Zoster 
1981 Hepatitis B (plasma derived)  2008 Rotavirus (monovalent)  
1983 Pneumococcus polysaccharide (23-valent)  2009 Japanese encephalitis  (Vero cell) 
1985 Haemophilus influenzae type b polysaccharide  2009 Cholera (WC only)  
1986 Hepatitis B surface antigen recombinant  2009 Human papillomavirus recombinant (2-valent)  
1987 H. influenzae type b conjugate a 2010 Meningococcal type A conjugate (monovalent) 
1989 Typhoid (Salmonella Ty21a)  2010 Pneumococcal conjugate (13-valent)  
1991 Cholera (WC-rBS) 2014 Human papillomavirus (9-valent)  
1992 Japanese encephalitis (mouse brain)  2014 Meningococcal type B (fH factor)  
1993 Cholera (recombinant toxin B)  2015 Ebola (unlicensed) b 
1994 Typhoid (Vi) polysaccharide  2015 Malaria c 
1994 Cholera (attenuated)  2015 Dengue  
1995 Varicella  2015 Meningococcal type B d 
1996 Hepatitis A  2016 Cholera (oral)  
1996 Pertussis (Acellular) 2018 Typhoid conjugatea 
1998 Lyme OspA 2006 Human papillomavirus recombinant (4-valent)  
1999 Meningococcal conjugate (group C) a 2006 Rotavirus (attenuated and new reassortants)  
 1037 
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Table 2: From discovery to sustainable impact of immunization: overcoming four major hurdles  1040 
  Issues Selected actions needed  
First hurdle: from discovery to early 
clinical development  
 Few discoveries make it to actual products 
 High risk for companies  
 Safety key issue 
 Incentives for industry for vaccines with no high 
income countries market 
 Public-private partnerships and philanthropy  
 
Second hurdle: from early clinical 
development to  large efficacy trials 
 Very expensive–two thirds of total costs of new 
vaccine development 
 Particularly challenging for vaccine candidates 
without high income market potential 
 Safety major issue, besides immunogenicity and 
efficacy 
 Complex road to licensure 
 Can take 3 to 10 years or longer 
 End-to-end product planning Need for major boost 
from private and public  
funding 
 Clinical trial capacity and rationalizing trial 
methodology 
 Regulatory harmonization and speed 
 Manufacturing availability for GMP-  
products to be used in trials 
  
Third hurdle: from vaccine licensure 
to  broad scale implementation 
 Dependent on policy recommendations, cost 
effectiveness deliberations, and political priority  
 Country capacity to take on new vaccines i.e. – 
human and financial resources and the time to build 
political support and community demand 
 Logistical issues, e.g. cold chain, procurement 
management, organisation of vaccination to ensure 
equity of access  
 Supply not always sufficient 
 Highly variable time-line by country 
 End-to-end product solution 
 National and international funding, Gavi  
transition management, tendering processes. 
 National regulatory harmonisation 
 Policy clarification and political leadership 
 Manufacturing capacity  
 Research on full societal value of vaccine assessment,  
        implementation research and relevant  
        cost-effectiveness models 
 Equity of access 
        
Fourth hurdle: achieving consistent , 
long term supply and demand 
sustainability  
 Continuing concern for every national immunisation 
programme   
 Issues may arise even after years of implementation 
 Complex interplay of service delivery, supply and 
demand, societal trust, political and humanitarian 
conflicts  
 Never ending  
 
 Policy and political commitment 
 Sustainable funding 
 Management and logistics 
 Tender processes 
 Manufacturing capacity 
 good communication, safety surveillance and 
vigilance, including promptly addressing safety 
signals and signs of vaccine hesitancy  
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Figures 1042 
 1043 
Figure 1. Vaccines across the human life cycle  1044 
Legend: Not only do vaccines provide important health benefits for all stages in life. They also do so 1045 
for travellers, health care workers as well as those who are in special health conditions.  1046 
Note: The list of vaccines by different phases of life-course are illustrative, rather than exhaustive, 1047 
and do not imply these are universally recommended for each life phase in all countries.  Vaccines 1048 
recommended by WHO by phase of lifecourse is available at 1049 
https://www.who.int/immunization/policy/immunization_tables/en/ (last accessed: 3 September 1050 
2019).   1051 
Figure 2. Coverage of DTP3 (containing products) immunisation over time globally, 1052 
combining coverage and regional variations, 1980-2018 1053 
Legend: The coverage of DTP3 immunisation improved rapid in the 80s with large regional 1054 
variations. Stagnation over the last 10 years meant 19.4 millions children remained un- or under-1055 
vaccinated.  1056 
Solid lines represent regional coverages. Vertical bars represent global coverages with percentages 1057 
showen at the top of each bar. 1058 
Source:  WHO/UNICEF coverage estimates 2018 revision, July 2019. 1059 
Note: DTP3: Diphtheria, tetanus, and pertussis; AFR, AMR, EMR, EUR, SEAR, and WPR are World 1060 
Health Organization subregions of Africa, Americas, Eastern Mediterranean, Europe, South-East Asia, 1061 
and Western Pacific, respectively.  1062 
Reprinted from “Progress Towards Global Immunization Goals - 2018: Summary presentation of key 1063 
indicators”, updated July 2019, WHO/UNICEF, “Global and Regional Immunization coverage with 1064 
three doses of diphtheria, tetanus, and pertussis (DTP3) containing vaccines, 1980-2018, global 1065 
coverage at 86% in 2018”, Copyright (2019).  1066 
 1067 
Figure 3 . Global Confidence in Vaccine Safety, 2018  1068 
Legend: Levels of confidence in vaccine safety varied considerably across countries and regions with  1069 
a number of countries showing very low levels of confidence.  1070 
The colour chart at the bottom shows increasing levels of confidence from red and dark green.  1071 
Source: Vaccine Confidence Index™ data from Wellcome 2018 Global Monitor 144 country survey on 1072 
Trust in Sceince and Health.  1073 
Note: The question asked in the survey is “vaccines are safe?”. 1074 
Map Credit: Alexandre De Figueiredo, The Vaccine Confidence Project  1075 
Figure 4. Changing levels of vaccine confidence in the Philippines between 2015 and 1076 
2019 (in percentages) 1077 
Legend: Dramatic fall in public confidene in vaccine safety in the Phillipines due partly to the impat 1078 
of social media and local politics  1079 
The months and years of the surveys conducted are represented by the verical bars in different 1080 
colours.  1081 
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Source: The Vaccine Confidence Project, Data collected by Gallup International (PSRC) 1082 
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